AU2005269765A1 - Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform - Google Patents

Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform Download PDF

Info

Publication number
AU2005269765A1
AU2005269765A1 AU2005269765A AU2005269765A AU2005269765A1 AU 2005269765 A1 AU2005269765 A1 AU 2005269765A1 AU 2005269765 A AU2005269765 A AU 2005269765A AU 2005269765 A AU2005269765 A AU 2005269765A AU 2005269765 A1 AU2005269765 A1 AU 2005269765A1
Authority
AU
Australia
Prior art keywords
composition
man
glycan
glcnac
immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005269765A
Other languages
English (en)
Inventor
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycofi Inc
Original Assignee
Glycofi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc filed Critical Glycofi Inc
Publication of AU2005269765A1 publication Critical patent/AU2005269765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
AU2005269765A 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform Abandoned AU2005269765A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58993704P 2004-07-21 2004-07-21
US58991304P 2004-07-21 2004-07-21
US60/589,937 2004-07-21
US60/589,913 2004-07-21
PCT/US2005/025662 WO2006014685A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a man3glcnac2 glycoform

Publications (1)

Publication Number Publication Date
AU2005269765A1 true AU2005269765A1 (en) 2006-02-09

Family

ID=35285633

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005269765A Abandoned AU2005269765A1 (en) 2004-07-21 2005-07-19 Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform

Country Status (5)

Country Link
EP (1) EP1771480A1 (ja)
JP (1) JP2008512354A (ja)
AU (1) AU2005269765A1 (ja)
CA (1) CA2573541A1 (ja)
WO (1) WO2006014685A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CL2007002926A1 (es) 2006-10-12 2008-05-16 Genentech Inc Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
US8080415B2 (en) 2008-09-26 2011-12-20 Eureka Therapeutics, Inc. Modified host cells and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9932599B2 (en) 2015-03-02 2018-04-03 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
EP3795586A3 (en) 2016-03-16 2021-06-23 Conagen Inc. Production of proteins in labyrinthulomycetes
CN109923206A (zh) 2016-11-01 2019-06-21 合成基因组股份有限公司 修饰的糖蛋白和糖肽的表达
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
CA3210709A1 (en) * 2021-03-23 2022-09-29 Glycoera Ag Glycan-mediated protein degradation
EP4314052A1 (en) * 2021-03-23 2024-02-07 Glycorea AG Mannose 3 glycan-mediated protein degradation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
KR101001243B1 (ko) * 2001-12-27 2010-12-17 글리코파이, 인크. 포유동물-유형 탄수화물 구조의 설계 방법

Also Published As

Publication number Publication date
EP1771480A1 (en) 2007-04-11
WO2006014685A1 (en) 2006-02-09
CA2573541A1 (en) 2006-02-09
JP2008512354A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
US20060034830A1 (en) Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034829A1 (en) Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060034828A1 (en) Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060029604A1 (en) Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060024304A1 (en) Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20090162377A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20060257399A1 (en) Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
AU2005269759A1 (en) Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
AU2005269763A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
WO2006071856A2 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
AU2005269765A1 (en) Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform
US20090136525A1 (en) Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform
US20090226464A1 (en) Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
AU2005322617A1 (en) Immunoglobulins comprising predominantly a Ga1G1cNAcMan5GlcNAc2 glycoform
AU2005269713A1 (en) Immunoglobulins comprising predominantly a Man5GlcNac2 glycoform
AU2005269712A1 (en) Immunoglobulins comprising predominantly a GlcNAcMan5GlcNAc2 glycoform
CN101001876A (zh) 包含占优势的GlcNacMAN5GLCNAC2糖形的免疫球蛋白

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period